1. Taiwan Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
SynCore Biotechnology Co., Ltd.

SynCore Biotechnology Co., Ltd.

TTPEX:4192
17.00
TWD
-0.45
(-2.58%)
-1.33EPS
705.06MMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.06
0.35
0.98
0.41
0.43
0.37
0.53
0.47
0.22
0.52
0.63
0.66
0.77
0.75
Basic EPS, GAAP
-8.17
-16.06
-11.5
-9.65
-13.61
-14.28
-16.71
-14.12
-14.87
-6.14
-1.19
-1.54
-1.3
-1.33
Free Cash Flow per Basic Share
-8.58
-17.29
-17.31
-12
-11.39
-13.47
-17.32
-11.42
-7.51
-6.85
-2.59
-1.41
-1.1
-0.93
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
39.07
56.28
52.89
50.96
38
31.23
23.16
19.38
14.18
7.97
10.16
8.38
6.99
6.23
Tangible Book Value per Share
36.73
47.27
34.19
37.14
26.22
22.99
17.43
15.36
11.55
6.1
8.7
7.13
5.93
5.28
Basic Weighted Avg Shares
13
14
16
17
19
21
24
28
31
31
32
35
35
35
Sales/Revenue/Turnover
1
5
15
7
8
8
13
13
7
16
20
23
27
26
Operating Margin (%)
-14,235.78
-5,066.71
-1,330.82
-3,532.44
-3,192.58
-3,906.36
-3,212.67
-2,966.74
-6,609.3
-1,207.5
-225.3
-247.49
-174.52
-185.77
Depreciation Expense
8
11
28
46
49
47
53
56
52
40
20
18
18
18
Net Income, GAAP
-106
-231
-182
-162
-258
-294
-409
-399
-459
-189
-38
-54
-46
-47
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-13,922.54
-4,561.94
-1,178.09
-2,351.97
-3,167.89
-3,816.86
-3,151.36
-2,991.29
-6,608.98
-1,189.8
-189.01
-232.6
-169.19
-178.54
Working Capital
408
619
427
699
447
482
406
394
329
162
289
238
205
176
LT Debt
- -
- -
- -
- -
- -
- -
18
5
- -
1
- -
1
- -
4
Total Equity
549
897
843
966
721
707
612
561
443
249
357
295
246
219
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
-27.57
-31.98
-20.94
-17.94
-30.59
-41.21
-61.97
-68.04
-91.4
-54.53
-12.59
-16.66
-16.94
-19.31

Capital Structure

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
2
10
9
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
5
4
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
35
35
35
Market Capitalization
876
719
705

Working Capital

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
215
204
193
Cash, Cash Equivalents & STI
164
156
146
Accounts Receivable, Net
6
5
5
Inventories
10
8
6
Total Current Liabilities
10
18
17
Payables & Accruals
- -
- -
- -
ST Debt
2
10
9
Deferred Revenue
- -
- -
- -

Growth Rates

TWD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-9%
-11.1%
-16.65%
Free Cash Flow
-12.21%
-32.01%
-22.05%
Net Income, GAAP
0.15%
-19.43%
-15.71%
Sales/Revenue/Turnover
16.77%
27.87%
15.88%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
4
7
5
7
23
2025
5
8
6
7
27
2026
6
6
- -
- -
- -

Quarterly Earnings Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.38
-0.38
-0.41
-0.37
-1.54
2025
-0.39
-0.33
-0.23
-0.35
-1.3
2026
-0.37
-0.38
- -
- -
- -

Quarterly Dividends Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Chih-Wen Lee
Full Time Employees
40
Sector
Health technology
Industry
Pharmaceuticals: major
Address
84 Chung Shan Road Yilan TP Taiwan 269
IPO Date
Aug 29, 2013
Website
syncorebio.com
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
SynCore Biotechnology Co., Ltd specializes in the research, development, manufacturing, and sales of biotechnology products primarily focused on synthetic biology and biopharmaceutical applications. Its main products include synthetic peptides, protein reagents, gene synthesis services, custom biological reagents, and related biotech research materials. The company provides comprehensive solutions for pharmaceutical companies, research institutions, and healthcare markets across Taiwan and other parts of Asia. Founded in 2009 and headquartered in Taiwan, SynCore Biotechnology operates within the biotechnology industry, emphasizing advanced synthetic biology technologies that support drug discovery, biomedical research, and clinical applications. It is recognized for its innovation in delivery of customized biotech products tailored to scientific research needs. In recent developments within the last 1-2 years, SynCore Biotechnology has expanded its strategic partnerships and enhanced its product portfolio by launching innovative synthetic biology service offerings designed to accelerate pharmaceutical R&D. It has also engaged in collaborations aimed at broadening its market presence and strengthening technological capabilities in peptide synthesis and genetic engineering services. These steps signify a strategic shift toward integrated biotech solutions with a focus on high-value-added products and services to meet growing demand in Asia's biopharma sector. Overall, SynCore Biotechnology Co., Ltd stands as a key player in Taiwan's synthetic biology and biotechnology landscape, supplying a diverse range of molecular biology products and custom services with an expanding footprint in the Asia-Pacific region.